FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808918705> ?p ?o ?g. }

• W2808918705 abstract "Bisphosphonates are recommended for use as first-line therapy for the prevention and treatment of glucocorticoid-induced osteoporosis in adults. However, the appropriate usage of bisphosphonates for the prevention or treatment of glucocorticoid-induced osteoporosis in children remains unclear.We performed a cross-sectional study to clarify the factors associated with the development of glucocorticoid-induced bone loss and osteoporosis in patients with childhood-onset rheumatic disease and to investigate the impact of the early use of alendronate. We recruited 39 patients with childhood-onset rheumatic disease who were evaluated to detect bone loss or osteoporosis at 3 months to 1.5 years after the initiation of treatment. The primary outcome of the study was the presence of bone loss or osteoporosis at the initial evaluation of the bone mineral density after at least 3 months of glucocorticoid therapy.Bone loss and a history of fracture were found in 56 and 18% of the participants, respectively. Weekly oral alendronate therapy (median, 25.4 mg/m2) had been started by the time of the evaluation of osteoporosis in 46% of the participants and within 3 months after the start of glucocorticoid in 31% of the participants. There were no significant differences between the participants with bone loss (wBL group) and without bone loss (w/oBL group) in terms of gender, primary disease, or the age at the onset of primary disease. In terms of glucocorticoid use, there was no significant difference in the age at the start of glucocorticoid therapy, the length of glucocorticoid use, or the dose of glucocorticoids. The proportion of patients in the w/oBL group who received alendronate within 3 months after the start of glucocorticoid therapy was significantly greater than that in the wBL group. In the logistic regression analysis, only alendronate therapy within 3 months after the start of glucocorticoid therapy had a statistically significant effect on the development of bone loss (OR, 0.08; 95% CI, 0.02-0.43). The analysis did not reveal any factors associated with the development of osteoporosis.The early use of alendronate may have a preventive effect against the development of bone loss in glucocorticoid-treated patients with childhood-onset rheumatic disease." @default.
• W2808918705 created "2018-06-29" @default.
• W2808918705 creator A5005354494 @default.
• W2808918705 creator A5008512966 @default.
• W2808918705 creator A5014108118 @default.
• W2808918705 creator A5021274281 @default.
• W2808918705 creator A5033779805 @default.
• W2808918705 creator A5035468036 @default.
• W2808918705 creator A5037548640 @default.
• W2808918705 creator A5039402819 @default.
• W2808918705 creator A5069225878 @default.
• W2808918705 creator A5079943912 @default.
• W2808918705 creator A5081545180 @default.
• W2808918705 creator A5084991542 @default.
• W2808918705 creator A5089406218 @default.
• W2808918705 creator A5091701897 @default.
• W2808918705 date "2018-06-18" @default.
• W2808918705 modified "2023-09-26" @default.
• W2808918705 title "Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study" @default.
• W2808918705 cites W1966051039 @default.
• W2808918705 cites W1975096117 @default.
• W2808918705 cites W1991114147 @default.
• W2808918705 cites W1993232754 @default.
• W2808918705 cites W1993731489 @default.
• W2808918705 cites W1998752290 @default.
• W2808918705 cites W2044178924 @default.
• W2808918705 cites W2050352060 @default.
• W2808918705 cites W2059709589 @default.
• W2808918705 cites W2065388026 @default.
• W2808918705 cites W2095741166 @default.
• W2808918705 cites W2110706792 @default.
• W2808918705 cites W2146591423 @default.
• W2808918705 cites W2166380219 @default.
• W2808918705 cites W2622691876 @default.
• W2808918705 doi "https://doi.org/10.1186/s12969-018-0258-5" @default.
• W2808918705 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6006935" @default.
• W2808918705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29914510" @default.
• W2808918705 hasPublicationYear "2018" @default.
• W2808918705 type Work @default.
• W2808918705 sameAs 2808918705 @default.
• W2808918705 citedByCount "7" @default.
• W2808918705 countsByYear W28089187052018 @default.
• W2808918705 countsByYear W28089187052020 @default.
• W2808918705 countsByYear W28089187052021 @default.
• W2808918705 countsByYear W28089187052022 @default.
• W2808918705 crossrefType "journal-article" @default.
• W2808918705 hasAuthorship W2808918705A5005354494 @default.
• W2808918705 hasAuthorship W2808918705A5008512966 @default.
• W2808918705 hasAuthorship W2808918705A5014108118 @default.
• W2808918705 hasAuthorship W2808918705A5021274281 @default.
• W2808918705 hasAuthorship W2808918705A5033779805 @default.
• W2808918705 hasAuthorship W2808918705A5035468036 @default.
• W2808918705 hasAuthorship W2808918705A5037548640 @default.
• W2808918705 hasAuthorship W2808918705A5039402819 @default.
• W2808918705 hasAuthorship W2808918705A5069225878 @default.
• W2808918705 hasAuthorship W2808918705A5079943912 @default.
• W2808918705 hasAuthorship W2808918705A5081545180 @default.
• W2808918705 hasAuthorship W2808918705A5084991542 @default.
• W2808918705 hasAuthorship W2808918705A5089406218 @default.
• W2808918705 hasAuthorship W2808918705A5091701897 @default.
• W2808918705 hasBestOaLocation W28089187051 @default.
• W2808918705 hasConcept C126322002 @default.
• W2808918705 hasConcept C187212893 @default.
• W2808918705 hasConcept C198451711 @default.
• W2808918705 hasConcept C2776169692 @default.
• W2808918705 hasConcept C2776541429 @default.
• W2808918705 hasConcept C2776886416 @default.
• W2808918705 hasConcept C2779329777 @default.
• W2808918705 hasConcept C2780841215 @default.
• W2808918705 hasConcept C71924100 @default.
• W2808918705 hasConceptScore W2808918705C126322002 @default.
• W2808918705 hasConceptScore W2808918705C187212893 @default.
• W2808918705 hasConceptScore W2808918705C198451711 @default.
• W2808918705 hasConceptScore W2808918705C2776169692 @default.
• W2808918705 hasConceptScore W2808918705C2776541429 @default.
• W2808918705 hasConceptScore W2808918705C2776886416 @default.
• W2808918705 hasConceptScore W2808918705C2779329777 @default.
• W2808918705 hasConceptScore W2808918705C2780841215 @default.
• W2808918705 hasConceptScore W2808918705C71924100 @default.
• W2808918705 hasIssue "1" @default.
• W2808918705 hasLocation W28089187051 @default.
• W2808918705 hasLocation W28089187052 @default.
• W2808918705 hasLocation W28089187053 @default.
• W2808918705 hasLocation W28089187054 @default.
• W2808918705 hasOpenAccess W2808918705 @default.
• W2808918705 hasPrimaryLocation W28089187051 @default.
• W2808918705 hasRelatedWork W1472547345 @default.
• W2808918705 hasRelatedWork W1984223009 @default.
• W2808918705 hasRelatedWork W2006855822 @default.
• W2808918705 hasRelatedWork W2081115542 @default.
• W2808918705 hasRelatedWork W2086983021 @default.
• W2808918705 hasRelatedWork W2129644291 @default.
• W2808918705 hasRelatedWork W2421733334 @default.
• W2808918705 hasRelatedWork W2462113375 @default.
• W2808918705 hasRelatedWork W2894245327 @default.
• W2808918705 hasRelatedWork W3158157237 @default.
• W2808918705 hasVolume "16" @default.
• W2808918705 isParatext "false" @default.
• W2808918705 isRetracted "false" @default.
• W2808918705 magId "2808918705" @default.

• next